Skip to main content
Public beta This website is in public beta – please give your feedback.

Example clinical scenario

A three-year-old-girl presents with a large head, short limbs relative to her trunk and mildly bowed legs. Her growth parameters were:

  • weight: 1.34 standard deviations (1.34SD) above the mean (on the 91st centile);
  • height: 0SD (on the 50th centile); and
  • occipital frontal circumference (OFC): 3SD above the mean (above the 99.6th centile).

She is the first child of healthy, unrelated parents of average stature. Her mother is 33 years old and her father is 40 years old.

When to consider genomic testing

You should consider genomic testing if your patient has clinical features strongly suggestive of hypochondroplasia, which may include:

  • shortening of the proximal (rhizomelia) or middle (mesomelia) segments of the limbs;
  • short stature (often 2–3SD below the mean, though it can be milder), or normal stature with limb-trunk disproportion;
  • relative macrocephaly;
  • joint laxity (often mild);
  • broad hands and feet with brachydactyly (short digits); and
  • less commonly:
    • lumbar lordosis;
    • scoliosis;
    • mild to moderate intellectual disability;
    • temporal lobe epilepsy;
    • adult-onset osteoarthritis; and
    • acanthosis nigricans.
  • Radiological features include:
    • brachydactyly;
    • short long bones with metaphyseal flare;
    • shortened squared ilia;
    • short, broad femoral neck; and
    • narrowed inferior lumbar interpedicular distances.

Antenatal scans can show a short femur or shortened long bones in some cases.

What do you need to do?

  • Consult the National Genomic Test Directory. From here you can access the rare and inherited disease eligibility criteria, which provides information about individual tests and their associated eligibility criteria. You can also access a spreadsheet containing details of all available tests.
  • To find out which genes are included on different gene panels, see the NHS Genomic Medicine Service (GMS) Signed Off Panels Resource.
  • If you suspect hypochondroplasia, the correct test to order is:
    • R382 Hypochondroplasia: This is targeted testing for the most common FGFR3 gene causative variants (rather than sequencing of the whole gene).
  • If R382 is negative but hypochondroplasia is still suspected, discuss further testing options with your laboratory (other options, such as FGFR3 gene Sanger sequencing, may or may not be available in an NHS diagnostic setting).
  • If you feel there are other likely diagnoses for the presentation, you may wish to consider the following tests:
  • If a family member already has a known hypochondroplasia FGFR3 causative variant, cascade testing can be carried out to identify other affected individuals. Testing relatives when the molecular basis is confirmed in the family may not be useful unless there is a clear rationale for doing so – for example, where the clinical diagnosis in the relative is in doubt. In this situation, the laboratory will test for the known familial variant only. First-degree relatives may be eligible for genomic counselling, at which point subsequent testing (R240 Diagnostic testing for known mutation(s)) can be arranged.
  • Requesting R104 and R27 requires authorisation from clinical genetics. R27 is a large whole genome sequencing (WGS) ‘super-panel’ (a panel comprised of several different constituent panels forming one large panel). As both these tests are undertaken using WGS, you will need to:
  • For tests that do not include WGS, including R382, R390 and R28:
    • you can use your local Genomic Laboratory Hub test order and consent (RoD) forms; and
    • parental samples may be needed for interpretation of the child’s result. Parental samples can be taken alongside that of the child, and their DNA stored, or can be requested at a later date if needed.
  • All the above tests are DNA based, so an EDTA sample (purple topped tube) is required.
  • Information about patient eligibility and test indications was correct at the time of writing. When requesting a test, please refer to the National Genomic Test Directory to confirm the right test for your patient.

Resources

For clinicians

For patients

↑ Back to top
  • Last reviewed: 27/06/2024
  • Next review due: 27/06/2025
  • Authors: Dr Ramanand Jeeneea
  • Reviewers: Dr Danielle Bogue, Dr Emile Hendriks, Dr Ataf Sabir